United Therapeutics (UTHR -0.44%) has once again received a rejection from the FDA for its oral Remodulin for pulmonary arterial hypertension. In this video, Motley Fool health-care analyst David Williamson tells investors why this resubmission may have been too soon, what the company would need to do before the next resubmission to have a chance at approval, and who the hidden losers are in this rejection.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.